• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Equivalent efficacy of Paclitaxel or Irinotecan for advanced gastric cancer

byAndrew Bishara
November 8, 2013
in Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

1.  There is no significant difference in treating advanced gastric cancer refractory to chemotherapy with Paclitaxel or Irinotecan.

Evidence rating level: 1 (Excellent) 

Study Rundown: Gastric cancer, though uncommon in the United States, is among the most common cancers diagnosed worldwide. Though the development of chemotherapy with fluoropyrimidine plus platinum has improved the prognosis of this disease, options for disease refractory to treatment are minimal. Many phase II trials evaluating the toxicities of paclitaxel or irinotecan have been completed, and currently taxanes and irinotecan are the two main options for second line chemotherapy. The purpose of this study is to directly compare these therapies in order to guide the management of these patients.

At the conclusion of the study, the authors found that there was no statistically significant difference between paclitaxel and irinotecan as second-line chemotherapy for advanced, refractory gastric cancer in overall survival, progression-free survival or in response rate. The activity, feasibility and tolerability of these treatments were also comparable. On the basis of these results, the study authors concluded that both drugs are reasonable second line therapies. Their findings will also serve as a basis for future trials evaluating additional second line therapies for advanced gastric cancer. These results are strengthened by the design of this trial, which involved randomizing patients from 37 centers in Japan under controlled conditions.

However, it should be noted that this was an open-label trial, thus introducing possible researcher biases or patient behavior changes that could have influenced the outcome of this study. Furthermore, though it was a multi-center trial, all patients were Japanese, and their primary chemotherapy with S-1 and cisplatin may not reflect current practices in other countries. The results of this trial are also not applicable to patients with severe peritoneal metastases.

Click to read the article in JCO

RELATED REPORTS

FOLFOX combined with nivolumab and trastuzumab in ERBB2-positive esophagogastric adenocarcinoma is an emerging therapy option

Intraperitoneal chemotherapy improves advanced ovarian cancer survival [Classics Series]

#VisualAbstract: Trastuzumab does not improve survival in patients with esophageal adenocarcinoma with HER2 overexpression

Relevant reading: Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial

In-Depth [Randomized, open-label trial]: In this phase III trial, the study authors randomly assigned a total of 223 patients to receive either Paclitaxel (80mg/m2 on days 1, 8 and 15, every 4 weeks) or Irinotecan (150mg/m2 on days 1 and 15, every 4 weeks). Patients with severe peritoneal metastasis were excluded. The primary outcome and end point was overall survival (OS), and secondary end points progression-free survival (PFS), response rate, adverse events, and the proportion of patients who received third-line chemotherapy. Median follow-up was 17.6 months.

Median OS was 9.5 months and 8.4 months in the paclitaxel and irinotecan groups, respectively (P = 0.38). Median PFS was 3.6 months and 2.3 months (P = 0.33). Treatment response rate was 20.9% and 13.6% (P = 0.24). Third-line chemotherapy was given to 89.8% of paclitaxel patients and 72.1% of irinotecan patients (P = 0.001). Overall, the two treatment arms differed only in terms of third-line chemotherapy, with no significance differences found in OS or PFS.

By Monica Parks and Andrew Bishara

More from this author: Rituximab linked with reduced chronic immune disease following stem cell transplantation, High-dose prophylaxis for hemophilia increases costs with minimal benefit, Ambrisentan found ineffective against idiopathic pulmonary fibrosis

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: gastric canceririnotecanpaclitaxel
Previous Post

One-on-one training leads to improved virtual-reality laparoscopic performance

Next Post

Venous thromboemobolism after major cancer surgery not associated with increased mortality

RelatedReports

Oncology

FOLFOX combined with nivolumab and trastuzumab in ERBB2-positive esophagogastric adenocarcinoma is an emerging therapy option

July 4, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Hematology/Oncology Classics

Intraperitoneal chemotherapy improves advanced ovarian cancer survival [Classics Series]

June 30, 2022
#VisualAbstract: Ruxolitinib use may be associated with higher incidences of nonmelanoma skin cancers
StudyGraphics

#VisualAbstract: Trastuzumab does not improve survival in patients with esophageal adenocarcinoma with HER2 overexpression

April 27, 2022
#VisualAbstract: Solid organ transplant recipients are at an increased risk of developing non-melanoma skin cancers
StudyGraphics

#VisualAbstract: Nivolumab plus chemotherapy improves progression-free survival in gastric or gastroesophageal junction cancer

April 13, 2022
Next Post
Surgical learning curve: factors in minimally invasive mitral valve surgery

Venous thromboemobolism after major cancer surgery not associated with increased mortality

Intrarenal resistive index partially reflects renal graft outcome

Gastric bypass surgery reduces cardio-metabolic risk factors

Bariatric surgery may improve sexual function in obese women

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Early exposure to allergenic foods may reduce incidence of long-term food allergy
  • Risk of post-vitrectomy endophthalmitis may have increased during the COVID-19 pandemic
  • Bosniak classification system differentiates benign renal cysts from cystic carcinoma [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.